Lower extremity lymphedema caused by acquired immune deficiency syndrome – related Kaposi's sarcoma: Case report and review of the literature  by Allen, Peter J. et al.
Lower extremity lymphedema caused by 
acquired immune deficiency 
syndrome-related Kaposi's arcoma: Case 
report and review of the literature 
Peter J. Allen, MD, David L. Gillespie, MD, Robert R. Redfield, MD, and 
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A case of severe lymphedema of the lower extremity caused by obstruction by human 
immunodeficiency virus-associated Kaposi's sarcoma is presented. A review of the signs 
and symptoms of obstructive lymphedema and Kaposi's sarcoma is provided. Early 
recognition of this clinical entity may allow use of simple preventative measures and help 
to avoid this life- and limb-threatening situation. (J VASC SURG 1995;22:178-81.) 
The epidemic of acquired immune deficiency 
syndrome (MDS) has resulted in a dramatic increase 
in the prevalence of Kaposi's sarcoma. As a result 
complications related to this tumor are also being 
seen with increased frequency. Obstructive lymph- 
edema of the lower extremity is one such complica- 
tion. Recent studies have pointed to lymphatic 
endothelium as the progenitor cell line for Kaposi's 
sarcoma. Familiarity with the diagnosis of this 
sarcoma nd the different herapeutic strategies for 
both Kaposi's sarcoma nd lymphedema is necessary 
to decrease the significant morbidity rate associated 
with this clinical entity. In this article we report a case 
of severe lower extremity lymphedema caused by 
MDS-related Kaposi's sarcoma nd review its diag- 
nosis and management. 
CASE REPORT 
The patient is a 25-year-old man with human irnmuno- 
deficiency virus (HIV) (Walter Reed stage 21) with an HIV 
helper cell count (CD4) of 506 cells/mm 3 and intact 
delayed-type hypersensitivity skin testing. He was admitted 
with complaints of persistent bruising and edema of both 
feet (Fig. 1). Biopsies of the "bruises" revealed Kaposi's 
sarcoma. After initial improvement from local radiation 
therapy, he was readmitted 8 months later with swelling in 
both lower extremities and the scrotum. New sarcomatous 
lesions involving the thighs and hard palate were noted. A 
3-month regimen of chemotherapy with vincristine (2 mg) 
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and bleomycin (20 units) followed by interferon-~ (36 
million units/mZ/day) and radiation therapy were used to 
treat his right inguinal Kaposi sarcoma without success. 
The patient's right lower extremity l mphedema pro- 
gressed, resulting  massive lymph leakage and ultimately 
tissue breakdown and infection. Admission physical exami- 
nation revealed no adenopathy, oral thrush, or oral hairy 
leukoplakia. His right lower extremity was markedly 
edematous, with multiple lesions weeping lymphatic fluid. 
There was minimal edema of the opposite leg. The arterial 
examination result was normal, and there was no evidence 
of deep venous thrombosis by duplex examination. Com- 
puted tomography scanning of the abdomen/pelvis re- 
vealed adenopathy but no evidence of pelvic mass. 
The patient was restricted to bedrest with continuous 
elevation of his right lower extremity. Open leg wounds 
were dressed three times daily with silver nitrate (0.5%)- 
soaked bandages and disposable elastic bandages to provide 
compression. 
Despite initial improvement the patient had develop- 
ment of a rapidly progressive necrotizing fasciitis of his 
right leg. He received broad spectrum antibiotics to treat 
the Corynebacterium species found by blood cultures. To 
prevent life-threatening sepsis, the patient underwent 
emergency hemipelvectomy to obtain control of the 
infection. 
After operation the patient underwent intensive physi- 
cal therapy, recovered quickly, and was discharged from the 
hospital 2 weeks after surgery. The patient was monitored 
for 2 months after operation, during which time he 
remrued to a reasonable level of self-sufficiency. His 
convalescence was complicated, however, by aggressive 
recurrence of Kaposi's sarcoma t the site of amputation. 
He subsequently had development of sepsis caused by 
Pscudomonas organisms and died. 
DISCUSSION 
Although not often involved in the treatment of 
patients with AIDS-related illness, vascular surgeons 
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Fig. 1. Lower extremity lymphedema with prominent Kaposi's sarcoma lesions of foot. 
are being asked to see such patients with increasing 
frequency. The case presented in this study is repre- 
sentative of one of the more common '~vascular" pre- 
sentations of patients with HIV at our institution. 
Through increasing awareness and early recognition, 
vascular surgeons may offer some assistance to these 
patients in avoiding life- or limb-threatening compli- 
cations. 
Kaposi's sarcoma 
Obstructive lymphedema c used by AIDS-related 
Kaposi's sarcoma, although previously rare, is now 
being seen with increased frequency. To date there 
are four forms of Kaposi's sarcoma that have been 
described. 2 The classic and African forms were the 
first described and tend to be indolent diseases that 
are not associated with immunodeficiency. A third 
form of the disease, discovered in 1969, was de- 
scribed in kidney transplant recipients. It was from 
this description that the relationship between immu- 
nosuppression and Kaposi's sarcoma was hypothe- 
sized. The fourth and final form of Kaposi's arcoma 
is observed most commonly in patients with HIV. In 
contrast to other presentations of the disease, HIV- 
associated Kaposi's sarcoma is usually a systemic 
disorder.3,4 Extracutaneous involvement by this form 
has been reported to involve the lymph nodes, 
gastrointestinal tract, lung, brain, testis, pancreas, 
and aorta. 4
Although lymphedema h s been well described in 
the African form of Kaposi's sarcoma, it is now 
becoming increasingly recognized in the HIV- 
associated form. Lymphedema caused by HIV- 
associated Kaposi's sarcoma is a very difficult condi- 
tion to treat, often leading to fatal complications. The 
exact mechanism whereby Kaposi's sarcoma causes 
lymphedema is unclear. In some instances, lymphatic 
obstruction is believed to be caused by external 
compression of the lymphatics by the cutaneous le-
sions. Other research as pointed to lymphatic dys- 
fimction as the cause of Kaposi's sarcoma-related 
lymphedema with direct communications between 
cutaneous lesions and lymphatics, as well as the inter- 
mixing of blood and lymph, sRecent studies evaluat- 
ing the microscopic characteristics and anatomic dis- 
tribution of Kaposi's sarcoma have supported the 
hypothesis that the sarcoma arises from the lym- 
phatic endothelium itself. 68 For further support of 
this hypothesis, one should consider the rare case of 
Kaposi's sarcoma in which lymphatic involvement is 
the only manifestation f the sarcoma. 9 
Diagnosis 
Diagnosing lymphedema caused by Kaposi's 
sarcoma is often difficult. Various neoplasms or 
infections may also cause lymphedema in patients 
with HIV infection. The presence of Kaposi's lesions 
may be the only distinguishing feature; however, 
these lesions are frequently subtle in nature and often 
occur only late in the course of this disease. Therefore 
all patients with lymphedema should undergo avery 
careful skin examination. Kaposi's lesions are char- 
acteristically small, fleshy, red or purple nodules, 
often mistaken for ecchymoses. They can occur 
anywhere on the skin but most often occur on the 
plantar surfaces of the feet. 
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The diagnostic approach to the patient with 
AIDS and lower extremity swelling should begin 
with excluding proximal ymphatic or venous ob- 
struction. The measurement of lower extremity 
venous outflow may be achieved noninvasively b  use 
of techniques such as air plethysmography or duplex 
ultrasonography. Computed tomography or mag- 
netic resonance imaging may help to visualize pos- 
sible structural causes of lymphatic obstruction. 
Causes of proximal ymphatic obstruction in such 
patients include a pelvic malignancy, lymphadenopa- 
thy, or extracutaneous Kaposi sarcoma involvement. 
Diagnostic methods for elucidating the cause of lym- 
phatic obstruction are evolving. Recently, lympho- 
scintigraphy with technetium 99-human serum albu- 
min has been used in the evaluation of lymphedema 
caused by Kaposi's sarcoma. 1°This technique differs 
from conventional lymphangiography by providing 
visualization of the lymphatic architecture, as well as a 
functional assessment of the lymphatics, n Lympho- 
scintigraphy is much less invasive than either conven- 
tional ymphangiography or lymph node biopsy. 
Treatment 
Therapy in these patients must focus equally on 
the treatment ofthe underlying Kaposi's sarcoma, as 
well as the lymphedema. Chemotherapy, with vin- 
blastine used as a single agent or in combination, is 
the best available therapy at present for treating 
Kaposi's sarcoma, although the tumor is also radio- 
sensitive. 9 High-dose interferon-c~ has also been 
shown to be effective in patients with HIV who are 
without evidence of immune compromise. 12 
Efforts to improve lymphatic drainage are im- 
perative to prevent the significant morbidity associ- 
ated with lymphedema. Without early intervention, 
accumulation fthe protein-rich interstitial fluid will 
result in irreversible fibrosis of the subcutaneous 
tissues. Treatment must include compression and 
elevation. Pharmacologic agents uch as diuretics or 
coumarin (Benzopyrone) have also been used with 
limited success in reducing tissue volume. 13 In the 
case presented mechanical reduction in fluid content 
was attempted through the use of lower extremity 
elevation and compressive dressings. Sequential 
pneumatic compression ofextremity l mphedema is 
another very effective method of treatment. 14 This 
therapy, however, must be used early in the course of 
disease because studies have revealed that patients 
with fibrotic lymphedema respond poorly) s
The preservation of skin integrity is extremely 
important in the treatment of lymphedema. Skin 
disruption provides a portal of entry for infectious 
bacteria. I6 Lymphedematous limbs are particularly 
susceptible to bacterial and fungal infections. Appli- 
cation of emollients to the legs and feet helps prevent 
cutaneous desiccation and subsequent breakdown. 
The use of prophylactic systemic antibiotics in these 
patients is controversial. In the event that skin 
breakdown does occur, the use of topical antimicro- 
bial agents may be considered tominimize the risk of 
life-threatening sepsis from supra colonization in 
these patients with immunocompromised condi- 
tions. 
Surgical intervention should be considered only 
after medical treatment has been tried and has failed. 
Many different surgical procedures have been de- 
scribed that either attempt to repair or remove the 
dysfunctional lymphatics) 6 Limited success has 
been achieved with these operations, and thus 
surgery should not be used as an initial intervention. 
Surgical intervention may have a role in the control 
of spreading infection in these patients. As in this 
case the inability to prevent secondary infection 
and the development of necrotizing fasciitis re- 
sulted in the need for hip disarticulation to prolong 
life. 
Lymphedema caused by Kaposi's sarcoma is 
becoming more frequent because of the AIDS 
epidemic. Consequently, the vascular surgeon must 
become familiar with the presentation a d treatment 
of this disorder. Intervention should be directed at 
both the sarcoma nd the lymphedema to obtain 
optimal results. As illustrated inthis case report, early 
intervention is necessary to prevent the acute loss of 
life or limb from this very debilitating manifestation 
of HIV. 
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The Lifeline Foundation of the Society for Vascular Surgery and the International 
Society for Cardiovascular Surgery, North American Chapter, invites grant applications 
for funding of meritorious research by young surgical investigators. The awards are in- 
tended for surgeons who have completed their formal surgical education in general sur- 
gery and who have completed or are in an advanced training program in vascular surgery. 
To be considered for selection a candidate: 
1. Should be certified by the American Board of Surgery or have completed the 
requirements for certification 
2. Should submit an application within 5 years of completion of an approved vas- 
cular surgery residency training program 
3. Must have either a faculty appointment in an approved medical school in the 
United States or Canada or have received an academic appointment within the 
guidelines of the applicant's institution 
Grant awards are not intended to supplement salary, which will remain the responsi- 
bility of the institution in which the awardee holds an appointment. The awardee is 
expected to devote asignificant amount of time to the funded project. A progress report 
must be presented to the Executive Committee of the Foundation by the following April 
1, and, on completion of the project, a brief oral report is to be presented to the 
memberships of the two societies during a plenary session at the Joint Annual Meeting. 
A grant awards committee will review competitive applications. It is anticipated that 
two grants will be awarded annually totaling $50,000 each to include indirect costs. The 
$50,000 grant includes funding to enable the awardee to attend the Joint Annual Meeting 
of the Vascular Societies to receive his or her award in the year of selection. Each award 
will be for 1 year with the option to extend for an additional year. 
Holders of substantial research awards, such as an NIH ROI, FIRST Award, or 
similar support, are ineligible. The applicant must append to the application the abstracts 
of any funded or pending rants. 
Grant applications may be obtained from: 
Chairman 
The Lifeline Foundation 
Thirteen Elm St. 
Kesearch and Education Committee 
Manchester, MA 01944 
(508)526-8330 
The deadline for receiving applications in the Foundation office is January 15, 
1996. Funds will be awarded by July 1, 1996. 
